Condition: Prematurity · Respiratory Disease · Ventilator Lung; Newborn · Sponsor: Ministry of Health, Saudi Arabia
Use of caffeine citrate in late-preterm infants with respiratory distress is questionable. Oliphant and colleagues found in a recently published study that caffeine therapy use in late-preterm infants at a loading dose of 20 and 40 mg/kg and maintenance dose of 10 and 20 mg/kg/day reduces the incidence of intermittent hypoxia events by 61 and 67% respectively. The investigators hypothesized that caffeine will improve respiratory drive, prevent apnea, shorten the hospital stay and improve arousal state in late preterm infants. The investigators aim to study the effect of caffeine citrate on late preterm babies as regard duration of respiratory support, duration of hospital stay, respiratory morbidity, incidence and frequency of apnea.
This description comes directly from the study's public registry record.
Ohoud Almoualled, Dr · +966500550679 · o.doc2or@gmail.com
Always discuss trial participation with your own doctor first.
| King Salman Bin Abdulaziz Medical City | Madinah, Medina Region, Saudi Arabia | Recruiting |
| King Salman Bin Abdulaziz Medical City | Madinah, Saudi Arabia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06026163